Miikka Vikkula/LinkedIn
Dec 25, 2025, 13:41
Miikka Vikkula on a Treatment Advance: How Sirolimus Dosing Can Be Adapted for Vascular Malformations
Miikka Vikkula, Vice President at International Society for the Study of Vascular Anomalies (ISSVA), shared a post on LinkedIn:
“Congratulations Emmanuel on this online publication showing how sirolimus treatment can be adapted to patients’ needs. Most patients with slow-flow vascular malformations benefit to some extent, and many experience significant symptom reduction even with intermittent dosing. This is a big step forward in the multimodal management of vascular malformations”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Oct 17, 2026, 02:00How Antiphospholipid Syndrome Can Affect the Adrenal Glands – APS Foundation of America
-
Oct 17, 2026, 01:59Liza-Marie Johnson: How Far Should Clinicians Go to Influence Parents’ Decisions?
-
Oct 17, 2026, 01:54Jim Hoffman: The Importance of Self-Advocacy and Understanding Autoimmune Mechanisms
-
Oct 17, 2026, 01:53Kristopher Jonas: Listening to Patients and Recognizing the Donors Who Make Treatment Possible
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke